patients with locally advanced or metastatic pancreatic cancer treated on phase 1 clinical trials at a single institution.METHODS:The authors reviewed the records of consecutive patients with metastatic pancreatic cancer who were treated in the Phase I Clinical Trials Program at The University of Texas...
Assessing FLT3 protein expression in AML cells is crucial for the accurate identification and recruitment of patients for the imminent Phase I clinical trials of the Company's HEMO-CAR-T product candidate. The trials are expected to commence shortly at MD Anderson Cancer Center ("MD Anderson"), ...
Some investigator-initiated phase 1 trials combining US FDA approved agents allow patients less than 18 years. We sought to determine the relationship between clinical characteristics and survival outcomes of pediatric patients enrolled in adult-based phase I trials at MD Anderson Cancer Center and to...
These data led to the development of an optimized vaccine exclusively targeting KRAS-derived neoantigens that is being evaluated in a subset of patients in phase 2 of the clinical study. ClinicalTrials.gov registration: NCT03953235.This is a preview of subscription content, access via your ...
unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy.Outcome analyses were conducted for 212 consecutive patients admitted to The University of Texas MD Anderson Cancer Center ICU after being seen in the phase I clinic starting on May 1, ...
The primary objective of early-phase (phase I, or phase I/II) clinical trials of a given anticancer agent is to determine its optimal dose (OD) to be administered to a cancer patient, so as to obtain the highest efficacy while maintaining admissible toxicity. Thus, in oncology, early-phase...
First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern OncotherapeuticsIn the era of precision medicine the treatment options for cancer patients and subsequent outcomes are expected to improve. We present a review of patients enrolled in first-in-human Phase1...
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome Invariant natural killer T (iNKT) cells recognize abnormal cells, but their T cell receptor is not variable and kill cancerous or infected target cells without MHC I rest...
phase 1 trial in our analysis having only received one or two previous treatment lines for MBC, compared to 20% in the MD Anderson series. The response rate of 11.4% observed in our retrospective study combined with a significant number of patients obtaining clinical benefit, which was highest...
Although this study did not proceed to stage 2, there was an early efficacy signal with a very favourable toxicity profile. A phase 1/2 trial of tivozanib in combination with durvalumab is currently underway. Trial registration ClinicalTrials.gov NCT01835223, registered on 15 April 2013.Similar...